Optimer grosses $60m as it exits Taiwanese operation
This article was originally published in Scrip
Executive Summary
Optimer Pharmaceuticals has fully divested its remaining stake in the US firm's formerly wholly owned Taiwanese subsidiary Optimer Biotechnology Inc (OBI), as part of an ongoing effort to streamline operations and raise funds.